8-K: Boston Scientific Reports Strong Q4 and Full Year 2024 Results, Exceeding Expectations

Boston Scientific announced robust fourth quarter and full year 2024 results, with net sales reaching $4.561 billion for the quarter and $16.747 billion for the year, driven by strong performance across all segments and regions.

Summary

• Boston Scientific reported net sales of $4.561 billion for the fourth quarter of 2024, a 22.4% increase on a reported basis compared to the prior year period.
• The company's GAAP net income attributable to Boston Scientific common stockholders was $566 million, or $0.38 per share, compared to $504 million, or $0.34 per share, a year ago.
• Adjusted EPS for the quarter was $0.70, compared to $0.55 a year ago.
• For the full year 2024, net sales reached $16.747 billion, representing a 17.6% increase on a reported basis.
• GAAP net income attributable to Boston Scientific common stockholders for the full year was $1.853 billion, or $1.25 per share, compared to $1.570 billion, or $1.07 per share, a year ago.
• Full year adjusted EPS was $2.51, compared to $2.05 a year ago.
• The company's guidance for full year 2025 net sales growth is approximately 12.5% to 14.5% on a reported basis and 10% to 12% on an organic basis.
• The company estimates full year 2025 EPS on a GAAP basis in a range of $1.86 to $1.93 and estimates adjusted EPS of $2.80 to $2.87.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook, driven by strong financial results, successful acquisitions, and positive clinical trial data. The company's guidance for 2025 also indicates continued growth and profitability.

Positives

• Strong revenue growth across all segments, particularly in the Cardiovascular division.
• Significant growth in the U.S. market.
• Successful acquisitions of Axonics and Cortex, expanding the company's portfolio.
• Positive clinical trial results for WATCHMAN FLX and FARAPULSE Pulsed Field Ablation System.
• FDA approval and CE mark for Vercise Cartesia X and HX Directional Leads.
• CMS approval of a new transitional pass-through payment for the AGENT Drug-Coated Balloon.

Negatives

• GAAP net income per share for Q4 2024 was $0.38, below the company's guidance range of $0.41 to $0.43.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties, including economic conditions, competitive pressures, and regulatory changes.
• Manufacturing, distribution, and supply chain disruptions could impact future performance.
• Variations in outcomes of clinical trials and market studies could affect product adoption.
• The closing and integration of acquisitions may present challenges.
• Geopolitical events and public health emergencies could disrupt operations.

Future Outlook

The company estimates net sales growth for the full year 2025 to be in the range of approximately 12.5% to 14.5% on a reported basis and approximately 10% to 12% on an organic basis. Full year 2025 EPS is estimated to be in the range of $1.86 to $1.93 on a GAAP basis and $2.80 to $2.87 on an adjusted basis.

Management Comments

• 2024 was one of the best years in the history of Boston Scientific, fueled by our innovative portfolio, the launch of our FARAPULSE Pulsed Field Ablation System as well as significant clinical achievements and commercial excellence across businesses and regions, said Mike Mahoney, chairman and chief executive officer, Boston Scientific.
• We have a strong foundation for growth, and I am incredibly grateful for our talented global team and the opportunity to continue transforming the lives of millions of patients around the world.

Industry Context

Boston Scientific's strong performance reflects the overall growth in the medical device industry, driven by innovation, aging populations, and increasing demand for minimally invasive procedures. The acquisitions of Axonics and Cortex demonstrate a strategic focus on expanding into high-growth areas such as neuromodulation and electrophysiology.

Comparison to Industry Standards

• Medtronic, a major competitor in the medical device space, reported 5% revenue growth in their most recent quarter, while Boston Scientific reported 22.4% revenue growth.
• Stryker reported 13.3% sales growth in their most recent quarter, lower than Boston Scientific's 17.6% full year growth.
• The acquisition of Axonics is comparable to Medtronic's focus on neuromodulation, indicating a similar strategic direction in addressing unmet patient needs in this area.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and positive outlook.
• Employees may benefit from the company's continued growth and success.
• Patients may benefit from the company's innovative medical technologies.
• The company's acquisitions could impact suppliers and customers of the acquired companies.
• Creditors may view the company's strong financial performance favorably.

Next Steps

• The company will continue to focus on innovation and strategic acquisitions to drive future growth.
• Management will discuss these results with analysts on a conference call.
• The company will work to close and integrate the acquisitions of Bolt Medical, Inc. and Intera Oncology Inc.

Key Dates

Keywords

Financial Results, Boston Scientific, Net Sales, EPS, Acquisition, Cardiovascular, MedSurg, Guidance, Innovation, Medical Devices